Last day of trading of SPEC TO3 subscription warrants tomorrow, Nov. 27
The last day of trading of SpectraCure AB (publ) TO3 is Wednesday, November 27th, 2019. Subscription of shares supported by the warrants in the TO3 program, implies that every two (2) warrants entitles the holder to subscribe for one (1) new share in SpectraCure at the subscription price of SEK 6.50. If all warrants are fully […]
SpectraCure´s main owner subscribes in full for his share
SpectraCure's main owner and CEO Masoud Khayyami subscribes in full through his company Cardeon Futuring Finance his share in the company's warrants program TO3, corresponding to 1 653 382 warrants. Cardeon Futuring Finance's total holding in SpectraCure after the issue amounts to 2 480 073 shares. Prior to the acquisition Masoud Khayyami, privately and with companies […]
SpectraCure AB Quarterly Report (1 July to 30 September) 2019
Third quarter (1 July – 30 September 2019) Other income amounted to TSEK 692 (215). Profit after tax amounted to TSEK -3 054 (-1 922). Corresponding to SEK -0,04 (-0,03) kr per share before and after diluted earnings. Operating cash flow was TSEK -3 072 (-2 640). Cash as of 30 September amounted to TSEK 25 421 (2 185) TSEK. Equity ratio: 81 […]
The FDA’s initiative can provide faster market access for SpectraCure
During SpectraCure's ongoing clinical trial, the American FDA (Food and Drug Administration) has created an opening for faster product launch by changing the requirements for endpoints in clinical trials in cancer treatment. The changed requirements provide new opportunities that in the long term may entail faster market access. The FDA's initiative to admit shorter […]
SpectraCure at Stora Aktiedagen in Gothenburg
A new opportunity to listen to Masoud Khayyami, CEO of SpectraCure, will be at Stora Aktiedagen in Gothenburg November 4th. The SpectraCure Company presentation, including the status of current clinical study, will be held at 1.30 p m. The event will be streamed at www.aktiespararna.se/tv/live. Where: Hall G3, Svenska Mässan, Mässans Gata 24, Gothenburg For further information, contact: SpectraCure […]
SpectraCure to the Premier Segment of First North Growth Market
SpectraCure AB (publ) announces today that Nasdaq has approved the Company's application to move its stock trading to First North Premier Growth Market. The transfer is an important step towards a future listing on Nasdaq Stockholm’s main market. The trade in SpectraCure’s shares on First North Premier Growth Market will be initiated on Thursday, October […]
Correction: Improved treatment technology in the fight against prostate cancer is used directly in an ongoing clinical trial
Correction concerning inaccurate reference under the EU Market Abuse Regulation (MAR). The pressrelease without reference is found below. Improved treatment technology in the fight against prostate cancer is used directly in an ongoing clinical trial The collaboration between SpectraCure and the German company MedCom GmbH has reached a stage where the technology will be used […]
Improved treatment technology in the fight against prostate cancer is used directly in an ongoing clinical trial
The collaboration between SpectraCure and the German company MedCom GmbH has reached a stage where the technology will be used in SpectraCure's ongoing clinical study. The technology leads to increased precision, accuracy and safety in the treatment of recurrent prostate cancer. SpectraCure runs an EU-funded development project, together with MedCom GmbH. The purpose of the […]
SpectraCure presentations at investor meetings this fall
SpectraCure (http://www.spectcomracure.) will be presented at Småbolagsjakten Live, September 25th and at at Stora Aktiedagen, November 4th. SpectraCure will be presented at Småbolagsjakten Live, September 25th Welcome to come and listen when the CEO of SpectraCure, Masoud Khayyami, holds a company presentation at the investor meeting Småbolagsjakten Live.The event has attracted great interest and is already sold […]
SpectraCure strengthens the organization with a PR Manager
September 1st, 2019 Annika Andersson will start as PR Manager at SpectraCure. Annika has a long experience of public relations, media and communication both strategically and operationally and has for the past 16 years run a communication agency. Annika contributes with expertise, experience and commitment. – The new role is also an important strengthening to […]
